First Trust Advisors’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.25M | Sell |
113,354
-22,649
| -17% | -$1.64M | 0.01% | 1244 |
|
|
2026
Q1 | $9.27M | Sell |
136,003
-19,593
| -13% | -$1.39M | 0.01% | 1133 |
|
|
2025
Q4 | $11.8M | Buy |
155,596
+33,741
| +28% | +$2.45M | 0.01% | 1036 |
|
|
2025
Q3 | $7.48M | Sell |
121,855
-3,467
| -3% | -$181K | 0.01% | 1200 |
|
|
2025
Q2 | $6.12M | Sell |
125,322
-16,426
| -12% | -$780K | ﹤0.01% | 1270 |
|
|
2025
Q1 | $7.22M | Buy |
141,748
+7,985
| +6% | +$398K | 0.01% | 1158 |
|
|
2024
Q4 | $6.04M | Buy |
133,763
+25,881
| +24% | +$1.11M | 0.01% | 1258 |
|
|
2024
Q3 | $4M | Buy |
107,882
+29,283
| +37% | +$980K | ﹤0.01% | 1440 |
|
|
2024
Q2 | $2.4M | Sell |
78,599
-1,356,881
| -95% | -$44M | ﹤0.01% | 1619 |
|
|
2024
Q1 | $41.8M | Buy |
+1,435,480
| New | +$40.2M | 0.04% | 535 |
|
|
2023
Q4 | – | Sell |
-30,539
| Closed | -$684K | – | 2418 |
|
|
2023
Q3 | $684K | Sell |
30,539
-21,279
| -41% | -$791K | ﹤0.01% | 2077 |
|
|
2023
Q2 | $2.11M | Buy |
51,818
+19,376
| +60% | +$948K | ﹤0.01% | 1677 |
|
|
2023
Q1 | $1.57M | Sell |
32,442
-42,921
| -57% | -$1.96M | ﹤0.01% | 1802 |
|
|
2022
Q4 | $2.88M | Sell |
75,363
-20,476
| -21% | -$851K | ﹤0.01% | 1523 |
|
|
2022
Q3 | $4.81M | Buy |
95,839
+37,437
| +64% | +$1.83M | 0.01% | 1203 |
|
|
2022
Q2 | $2.34M | Buy |
58,402
+22,523
| +63% | +$790K | ﹤0.01% | 1658 |
|
|
2022
Q1 | $1.34M | Buy |
35,879
+22,378
| +166% | +$862K | ﹤0.01% | 1938 |
|
|
2021
Q4 | $538K | Buy |
+13,501
| New | +$517K | ﹤0.01% | 2274 |
|
|
2021
Q2 | – | Sell |
-55,740
| Closed | -$2.64M | – | 2535 |
|
|
2021
Q1 | $2.64M | Buy |
+55,740
| New | +$3.31M | ﹤0.01% | 1612 |
|
|
2020
Q4 | – | Sell |
-49,389
| Closed | -$2.31M | – | 2398 |
|
|
2020
Q3 | $2.31M | Sell |
49,389
-8,743
| -15% | -$430K | ﹤0.01% | 1295 |
|
|
2020
Q2 | $2.95M | Buy |
58,132
+12,011
| +26% | +$590K | 0.01% | 1188 |
|
|
2020
Q1 | $2.06M | Buy |
+46,121
| New | +$2.32M | ﹤0.01% | 1258 |
|
|
2019
Q4 | – | Sell |
-49,459
| Closed | -$1.67M | – | 2439 |
|
|
2019
Q3 | $1.67M | Buy |
49,459
+17,429
| +54% | +$759K | ﹤0.01% | 1640 |
|
|
2019
Q2 | $1.44M | Sell |
32,030
-51,372
| -62% | -$2.03M | ﹤0.01% | 1719 |
|
|
2019
Q1 | $3.14M | Sell |
83,402
-19,254
| -19% | -$646K | 0.01% | 1304 |
|
|
2018
Q4 | $3.52M | Sell |
102,656
-59,904
| -37% | -$2.15M | 0.01% | 1160 |
|
|
2018
Q3 | $7.64M | Buy |
162,560
+18,903
| +13% | +$782K | 0.01% | 927 |
|
|
2018
Q2 | $4.85M | Buy |
+143,657
| New | +$4.48M | 0.01% | 1112 |
|
|
2016
Q4 | – | Sell |
-13,421
| Closed | -$188K | – | 2486 |
|
|
2016
Q3 | $188K | Buy |
+13,421
| New | +$109K | ﹤0.01% | 2235 |
|
Other funds holding PTCT
RI
JT
First Trust Advisors's PTCT Position: Q2 2026 in Review
First Trust Advisors reduced its PTC Therapeutics (PTCT) stake by 17% in Q2 2026, selling an estimated $1.64M and leaving 113,354 shares worth $9.25M. The position accounts for 0.01% of the portfolio, ranked #1244.
First Trust Advisors first reported a position in PTCT in Q3 2016 and has held it in 29 quarters since. The position peaked at $41.8M in Q1 2024. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- First Trust Advisors held 113,354 shares of PTC Therapeutics worth $9.25M as of Q2 2026.
- First Trust Advisors sold 22,649 PTC Therapeutics shares in Q2 2026, an estimated $1.64M.
- PTC Therapeutics made up 0.01% of First Trust Advisors's portfolio in Q2 2026, its #1244 holding.
- First Trust Advisors first reported a position in PTC Therapeutics in Q3 2016 and has held it in 29 quarters since.
- First Trust Advisors's PTC Therapeutics position peaked at $41.8M in Q1 2024.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.